key: cord-1001874-unebt86s
authors: Rao, A.; R, R.; G, V.; C, S.; Ruthra, M.; Manichen, S.; SIGAMANI, A.; Reddy, R. k.
title: AYUSH medicine as add-on therapy for mild category COVID-19; an open label randomised, controlled clinical trial.
date: 2020-12-11
journal: nan
DOI: 10.1101/2020.12.06.20245019
sha: 726e5346df62fdd4f4c0fbc326aeebb612a7550e
doc_id: 1001874
cord_uid: unebt86s

Background: AYUSH formulations have a potential role in symptomatic treatment, preventing disease progression and improving quality of life in COVID-19 patients. Objective: To study the effect of AYUSH formulation (Kabasura Kudineer tablets, Shakti drops and Turmeric plus) as an add-on treatment in patients with mild COVID -19 Methodology: Single centre, two arms, open labelled randomized controlled trial with a total of 30 patients (15 in the intervention arm and 15 in the standard care arm). Intervention arm received a combination of 3 AYUSH formulation along with the standard of care treatment for 21 days. All patients were followed for 28 days. Symptom severity (using Modified Jackson scale), negative conversion of SARS-CoV-2 RNA (using RTPCR) and quality of life (WHOWOL BREF questionnaire) was assessed. Results: Fifteen patients (93.8%) in the intervention group and twelve patients (92.3%) in the standard care arm had complete resolution of symptoms (P value= 0.36). Negative conversion for SARS-CoV-2 was seen in thirteen patients (92.9%) in intervention arm and eleven patients (100%) in standard care arm at day 28 (P value = 0.56). There was no difference in the quality of life scores between the 2 groups. Conclusion: The use of Ayush interventions as add-on therapy did not negatively impact the clinical outcomes in COVID-19. This trial confirmed the safety and tolerability of Kabasura Kudineer tablets, Shakti drops and Turmeric plus tablets when used use among mild to moderate symptom category, of COVID-19. There were no serious adverse events in the treated group. There was no clinical progression of disease from baseline status and all trial participants recovered fully by day 28. A longer follow up and a larger sample size is recommended for future definitive trials with this alternative medicine (AYUSH) combination.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint

The study was initiated after ethics committee approval (NHMEC S38/2020) and informed consent was obtained from all study participants. All study related activities were conducted in accordance with the AYUSH (GCP-ASU) Guidelines for Good Clinical Practice, the ICMR National Ethical Guidelines for Bio medical and Health research involving human participants. This trial is being reported as per the CONSORT checklist. The study was registered in the Clinical trial registry of India (CTRI/2020/07/026371)

For the study we included uncomplicated cases of COVID-19 infection of either gender between 20 to 55 years of age, with no associated co-morbid illness. We excluded patients on immunosuppressive therapy, pregnant and lactating mothers and those with advanced stage of illness requiring emergency medical interventions.

The study was a single centre, open label. randomized controlled trial including a total of 30 patients with mild COVID symptoms. Patients were classified as Stage 1 and stage 2 depending on the lung symptoms. Stage 1 included patients with symptoms of headache, sore throat, fever, slight cough, malaise, and fatigue. Stage 2 included patients with cough, breathlessness, and pain in the chest with fever in addition to the symptoms mentioned in stage 1. Eligible patients were screened from the COVID ward.

After obtaining informed consent patients were randomized into either standard care only or standard care with AYUSH medicines.

Study data were collected and managed using REDCap electronic data capture tools Patients in the standard care received paracetamol, antitussives, vitamin C, Zinc, antibiotics and ivermectin. In addition, patients in the intervention arm received Kabasura Kudineer tablets (2 tablets taken thrice a day before food) and Shakti drops (6 drops with 100 ml of water thrice a day before food) for stage 1; Kabasura Kudineer tablets (2 tablets taken thrice a day before food) and Shakti drops (6 drops with 100 ml of water thrice a day before food) and Turmeric plus tablets (2 tablets thrice a day after is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint food) for stage 2. All the 3 formulations are GMP approved. Along with this, patients were advised dietary and lifestyle modifications such as consuming freshly prepared easily digestible, light diet; avoid using sweets and food which is heavy to digest, chilled, fried, oily, fermented food items, cold and refrigerated food /beverages.

Standard care was provided until symptom resolved and patient condition improved.

AYUSH medicines were given for a period of 21 days. Patients were monitored daily for improvement of symptoms, development of any adverse effects or disease progression until discharge followed by telephonic assessment at day 28. Symptom severity was assessed using Modified Jackson symptom severity score. Eight symptoms namely sneezing, nasal discharge, nasal congestion, sore throat, cough, headache, malaise, and fever were scored from 0 to 3 (0 for no symptoms, 1 for mild, 2 moderate and 3 for severe symptoms). (12) Patients were asked to rate their symptoms based on the severity. Quality of life was assessed using WHO QOL BREF questionnaire. It is a self-administered questionnaire with 26 items under 4 main domains (physical health, psychological health, social relationship and environment). Each item was given a score of 1 to 5 (1 when "very dissatisfied" and 5 when "very satisfied"). (13) RT PCR to test for SARS-Cov-2 negative conversion was done at day 14 and repeated weekly till day 28 till they turn negative.

Safety assessment was done based on symptom assessment, clinical examination and blood investigations. Blood investigations included complete blood count, blood sugar level, liver and renal function test performed at baseline, day 14 and day 21.

A total of 30 patients were planned for the study (15 in the standard care only and 15 in AYUSH plus standard care). Descriptive statistics was used for baseline characteristics. Continuous variables were expressed using mean and standard deviation. Categorical variables were expressed using frequency and percentage.

Proportion of patients achieving improvement in symptoms at day-7 was compared between 2 groups using Fischer exact test. Improvement in quality of life between the 2 groups on day 28 was compared using Mann Whitney U test. P value less than 0.05 was considered statistically significant.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint

A total of 30 patients were enrolled for the study (15 in each group). One patient was wrongly randomized into AYUSH plus standard arm making it 16 in the intervention arm and 14 in the standard care arm. (Figure -1) . Baseline characteristics were shown as per randomization and all patient characteristics were comparable between the 2 groups. The mean age was 27.2 ± 6.81 in the intervention arm and 28.20 ± 4.96 in the standard care arm. The predominant symptoms were fever (26.7% vs 33.3%), cough (26.7% vs 40%), sore throat (53.3% vs 40%), running nose (26.7% vs 33.3%), general weakness (66.7% vs 40%), and headache (33.3% vs 33.3%) in the intervention group and standard care group respectively. (Table-1) Data were analysed using modified intention to treat analysis (patients received at least one dose of the study drug and available for analysis). All patients completed the trial and discharged in stable condition. There was no loss to follow up by the end of 28 days. Modified Jackson score was analysed in 29 patients at day 7 (one not willing to continue) and WHOQOL score analysed in 28 patients (2 patients not willing for assessment). Fifteen patients in the intervention group and 12 patients in the standard group had complete resolution of symptoms by day 7. There was no significant difference in terms of symptom improvement between the 2 groups. Fifteen patients (93.8%) in the intervention group and twelve patients (92.3%) in the standard care arm had complete resolution of symptoms (P value= 0.36) ( Table-3 ). Though both the groups showed improvement in quality-of-life score, there was no significant difference in improvement of quality of life between the 2 groups. (Table-4) RTPCR testing at 14 days showed 6 patients (54.5%) in intervention arm and 7 patients (70%) in standard care arm negative for COVID (P value 0.39). By day 28, thirteen patients (92.9%) in intervention arm and 11 patients (100%) in standard care arm were negative (P value 0.56 Table- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint

One participant in the standard of care alone arm, required oxygen support on experiencing difficulty in breathing. This serious adverse event was recorded and reported to ethics committee. Three participants in the treatment group (AYUSH plus Standard of Care) experienced non related adverse events; one had uveitis, the other hyperglycaemia and one person experienced menorrhagia. They did not qualify to be reported as serious adverse events. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint difference in terms of negative conversion rate between the intervention arm and standard care both at day 14 (54.5% vs 70%, P value 0.39) as well as day 28 (92.9% vs 100%, P value 0.56) respectively. The patients in our study had low symptom severity score at baseline and showed complete resolution of symptoms by day 14. This may probably be the reason for the lack of improvement seen in the quality of life between the 2 groups. Also since this was a pilot study, the number of patients were small. These are the limitations of our study.

This trial concludes that a combination Kabasura Kudineer tablets, Shakti drops and Turmeric plus tablets used as an add on along with standard of care treatment of COVID-19 is safe. All the participants who received the combination did not experience clinical worsening of their illness. It can be considered as a safe alternative medicine add on therapy for COVID-19. Further studies are needed to evaluate the long term benefits in COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 11, 2020. ; https://doi.org/10.1101/2020.12.06.20245019 doi: medRxiv preprint

Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective

Features, Evaluation, and Treatment of Coronavirus

Global trends of clinical presentation of COVID-19

Unique epidemiological and clinical features of the emerging 2019 novel corona virus pneumonia (COVID-19) implicate special control measures

COVID-19)

COVID-19): A Review of Clinical Features

Guidelines for SIDDHA practitioners for COVID-19

A Mini review on the antiviral properties of ancient siddha medicine from India

Standardization in Vitro Antioxidant Activity and Brine Shrimp Lethality of A Polyherbal Formulation

Potential use of turmeric in COVID-19

Curcumin: a review of its' effects on human health

Predictors of Health-Related Quality of Life and Influencing Factors for COVID-19 Patients, a Follow-Up at One Month. Front

Postdischarge persistent symptoms and health-related quality of life after hospitalization for COVID-19